Global Platform Study Presents Results to Guide Care of Severely Ill Patients With COVID-19 Using Routinely Available Drugs – Simvastatin and Vitamin C
Retrieved on:
Wednesday, October 25, 2023
Science, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Hospitals, Clinical Trials, WHO, Urinary tract infection, Survival, FRCP, Patient, Vitamin C, Simvastatin, Royal Victoria Hospital, Montreal, Bronchopneumonia, MPH, Global Coalition Against Pneumonia, Oregon Health & Science University, University, Respiratory tract infection, JAMA, Professor, Vitamin, Multimedia, Queen's University Belfast, University of Pittsburgh School of Medicine, Learning, Critical Care Medicine (journal), COVID, Clinical trial, Intensive care unit, Hospital, NEJM, Probability, Pittsburgh, European Society of Clinical Microbiology and Infectious Diseases, Wilfrid Sellars, SUNY Downstate Health Sciences University, Hospice and palliative medicine, Intensive care medicine, Royal Victoria Hospital, UPMC, Consultant, Ohio State University Wexner Medical Center, Pharmaceutical industry, Dietary supplement, MD
Vitamin C is widely available around the world and was used in some settings for the treatment of COVID-19.
Key Points:
- Vitamin C is widely available around the world and was used in some settings for the treatment of COVID-19.
- Through harmonizing two clinical trials – REMAP-CAP and LOVIT-COVID – over 2500 patients in 20 countries took part, including both critically ill and non-critically ill patients with COVID-19 in hospital.
- It was shown that high dose vitamin C did not improve outcomes for patients.
- Intravenous Vitamin C for Patients Hospitalized with COVID-19: Two Harmonized Randomized Clinical Trials.